Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.41 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.41 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.39 |
| ▸ | MYLK | Q15746 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3988068 | 0.95 | MGLL (0.41) | MEN1KMT2ACACNA1FCACNA1DCACNA1S | |
| SCHEMBL14760554 | 0.93 | ALDH1A1 (0.43) | MEN1KMT2ACACNA1FCACNA1DCACNA1S | |
| SCHEMBL6194063 | 0.91 | CACNA1F (0.41) | MEN1KMT2ACACNA1FCACNA1DCACNA1S | |
| SCHEMBL6195392 | 0.90 | CACNA1F (0.40) | MEN1KMT2ACACNA1FCACNA1DCACNA1S | |
| SCHEMBL6641617 | 0.89 | CACNA1F (0.41) | MEN1KMT2ACACNA1FCACNA1DCACNA1S | |
| SCHEMBL4294571 | 0.86 | MGLL (0.42) | MEN1KMT2ACACNA1FCACNA1DCACNA1S | |
| SCHEMBL6247829 | 0.86 | CACNA1F (0.36) | MEN1KMT2ACACNA1FCACNA1DCACNA1S | |
| SCHEMBL6194820 | 0.82 | MAPT (0.47) | MEN1KMT2ACACNA1FCACNA1DCACNA1S | |
| SCHEMBL6644031 | 0.81 | MYLK (0.39) | MEN1KMT2ACACNA1FCACNA1DCACNA1S | |
| SCHEMBL6847771 | 0.79 | MEN1 (0.37) | MEN1KMT2ACACNA1FCACNA1DCACNA1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1021185-A4 | DIDHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6727257-B1 | HYPOTENSIVE AGENTS FOR INTRAOCULAR PRESSURE; ANTICHOLESTEROL AGENTS; RELAXING URINARY TRACT TISSUE; BENIGN PROSTATIC HYPERPLASIA, IMPOTENCY, AND CARDIOVASCULAR DISORDERS; ANTIARRHYTHMIA AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-01-24 | — | — | US | disclosed |
| US-6268369-B1 | ALPHA SUB 1 INHIBITORS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-07-31 | — | — | US | disclosed |
| US-6248747-B1 | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH ANTAGONISTS SELECTIVE FOR CLONED HUMAN ALPHA-1C RECEPTORS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-06-19 | — | — | US | disclosed |
| US-6245773-B1 | BENIGN PROSTATIC HYPERPLAMIA; REDUCTION OF INTRAOCULAR PRESSURE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-06-12 | — | — | US | disclosed |
| EP-1021185-A1 | DIDHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-07-26 | — | — | EP | disclosed |
| US-5942517-A | ANTAGONIST OF ALPHA(1C) RECEPTORS; TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-08-24 | — | — | US | disclosed |
| EP-0790826-A4 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 1998-11-11 | — | — | EP | disclosed |
| WO-1997042956-A1 | DIDHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-11-20 | — | — | WO | disclosed |
| EP-0790826-A1 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996014846-A1 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | QDPR, DPYD, ADRA1D | MEN1 2855/4885KMT2A 2886/4885CACNA1F 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.